Indian Frankincense, Boswellia
The dry extract obtained from the gum-resin from Boswellia tree is a powerfull antiinflamatory, used for the treatment of rheumatoid arthritis, inflammatory processes, inflammation and arthritic conditions, osteoarthritis, juvenile rheumatoid arthritis, myositis and fibrositis and colitis.
- Origin: Plant Based
- Source: Itself
- Type: Bioactive Compounds
- Age Range: Adults (18-60)
- Toxicity: May be toxic in high doses
- Outcomes: Bone and Joint Health, Symptoms of Osteoarthritis
What are Boswellia benefits?
Table of relations
Published articles about Boswellia and Symptoms of Osteoarthritis
Efficacy And Safety Of Meriva®, A Curcumin-phosphatidylcholine Complex, During Extended Administration In Osteoarthritis Patients
Curcumin, dosed at 1,000mg MERIVA (curcumin bound to phosphatidylcholine) taken in two divided dosages of 500mg, was safe and effective over a period of 8 months in alleviating clinical and biochemical symptoms of osteoarthritis in a population of middle-aged (43+/-2) persons with osteoarthritis. Reductions were noted in IL-6 (27%), IL-1b (65%), and cell adhesion factors.
A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort
In patients with osteoarthritis given 10g hydrolyzed collagen over six months appeared to reduce pain assessed by VAS and WOMAC, although no other parameter on WOMAC (stiffness, function, or total score) was affected by treatment relative to placebo.
A study in 60 people with advanced rheumatoid arthritis given supplementation of solubilized collagen (0.1mg for one month then 1mg for the next) noted a reduction in joint pain and stiffness to a degree greater than placebo, with four subjects reporting resolution of symptoms dependent on supplementation (as symptoms reemerged after three months supplement cessation).
Safety And Efficacy Of Undenatured Type II Collagen In The Treatment Of Osteoarthritis Of The Knee: A Clinical Trial
Supplementation of 40mg UC-II (undenatured CII) once daily for three months was able to improve symptoms of osteoarthritis as assessed by WOMAC, VAS, and Lequesne rating scales. The potency was comparable to a combination of glucosamine HCl (1,500mg) and chondroitin sulphate (1,200mg) on Lequesne and VAS, and more effective on WOMAC. There was no placebo control used in this study and medication was relatively well tolerated.
Treatment Of Rheumatoid Arthritis With Oral Type II Collagen. Results Of A Multicenter, Double-blind, Placebo-controlled Trial
Supplementation of four doses of CII to rheumatic patients (20mcg, 100mcg, 500mcg, or 2.5mg) over 24 weeks noted that the lower doses were associated with higher response rates than the higher doses, with the 19% response seen in placebo being outperformed by a 39% response in the 20mcg group (25% response in 2.5mg was not statistically significant). Response was determined by at least a 30% reduction in joint soreness with responses on ACR and the Paulus criteria, and when looking only at the 30% reduction in pain all treatment groups (excluding ACR and Paulus) performed somewhat equally. IgA and IgG antibodies were detected only in a few subjects, and appeared to predict responsiveness to therapy at all doses despite their specificity to CII or overall amounts being affected.
In a randomized, double-blind, placebo-controlled trial, 53 people with knee osteoarthritis were assigned to take 1,500 mg of a curcuminoid complex (95% curcuminoids) with 15 mg of piperine or placebo daily for 6 weeks. 25% of participants didn't complete the study and weren't analyzed. The primary outcome was the change in the Western Ontario And McMaster Universities Osteoarthritis Index (WOMAC), which assessed osteoarthritis symptoms broadly, including pain, function, and stiffness. The curcuminoid group saw a notable, statistically significant reduction in the global WOMAC scale score and pain, and an improvement in function compared with the placebo group, but not for stiffness. The secondary outcomes were pain on a visual analog scale, and score on the Lequesne’s pain functional index and the curcuminoid group saw notable, statistically significant improvements compared with the placebo group for both. The participants in the curcuminoid group tended to use fewer NSAIDs over the course of the study.
Product-evaluation Registry Of Meriva®, A Curcumin-phosphatidylcholine Complex, For The Complementary Management Of Osteoarthritis
200mg of MERIVA, taken at 200mg daily, was able to reduce symptoms of osteoarthritis and joint pain as assessed by the WOMAC rating scale and improve physical performance. C-Reactive Protein decreased only in the group with higher CRP at baseline, although to a very large degree (168 to 11.3mg/L)
Safety And Efficacy Of Curcuma Longa Extract In The Treatment Of Painful Knee Osteoarthritis: A Randomized Placebo-controlled Trial
In a randomized, single-blind, placebo-controlled trial, 120 participants with knee osteoarthritis were assigned to take either 1,000 mg of a turmeric extract (Turmacinᵀᴹ), 1,500 mg of glucosamine sulfate, the combination, or placebo daily for 6 weeks. The primary outcomes were pain, as assessed by visual analog scale (VAS) and Western Ontario and McMaster. Universities Osteoarthritis Index (WOMAC) and function as assessed by WOMAC. Pain on the VAS for the turmeric group was dramatically reduced compared with placebo and the combination group and was reduced more than in the glucosamine group, but this wasn't statistically significant. The reduction in WOMAC rating was also much larger and statistically significant compared with placebo, while only modestly larger than compared with placebo and the combination group. Clinical Global Impression change in the turmeric group was significantly greater than for placebo and glucosamine, but not for the combination, though the turmeric-only group saw a greater reduction. The joint tenderness, crepitation, effusion, and terminal limitation of movement were all significantly and potently reduced in the turmeric group compared with baseline, while the placebo group only saw modest reductions, none of which were statistically significant. No notable difference in adverse events was found compared with placebo, and participants in the turmeric group were less likely to use acetaminophen as a rescue medication.
Short-term Effects Of Highly-bioavailable Curcumin For Treating Knee Osteoarthritis: A Randomized, Double-blind, Placebo-controlled Prospective Study
In a randomized, double-blind, placebo-controlled trial, 50 participants with knee osteoarthritis were assigned to take 180 mg of curcumin (Theracurcumin) or placebo daily for 8 weeks. 18% of participants didn't complete the study and weren't analyzed. The curcumin group saw a notable reduction in pain compared with the placebo group, which was only statistically significant for the subset of participants with initial VAS scores of 0.15. Osteoarthritis symptoms as measured by the Japanese Knee Osteoarthritis Measure (JKOM) were somewhat improved in the curcumin group compared with the placebo group, but the difference wasn't statistically significant. The curcumin group tended to use less celecoxib than the placebo group throughout the study.
Efficacy And Safety Of Curcumin And Its Combination With Boswellic Acid In Osteoarthritis: A Comparative, Randomized, Double-blind, Placebo-controlled Study
In a randomized, double-blind, placebo-controlled trial, 201 participants with degenerative hypertrophic osteoarthritis were assigned to take 1,500 mg curcuminoids (BCM-95), 1050 mg curcuminoids with 450 mg Boswellia serrata, or placebo for 12 weeks. The primary outcomes were osteoarthritis pain and function assessed by WOMAC, and physical performance was assessed by OARSI-recommended tests. Total WOMAC score was somewhat reduced in the curcumin and combination groups compared with placebo, but only the combination group saw a statistically significant reduction. Pain was significantly improved compared with placebo in the combination group, but not stiffness or function, and while the curcumin group saw improvements compared with placebo, none of these were statistically significant. For the OARSI-recommended tests, the curcumin group saw notable, statistically significant improvements compared with the placebo group for the chair stand test and fast-paced walk test speed, but not for the time up and go test, or stair climb test, though it did see improvements. The combination group saw statistically significant improvements for all. There were no notable differences in adverse events between the curcumin and placebo groups (3% and 5.6% respectively), and the combination group saw somewhat more than either (10.6%).
Efficacy And Safety Of Curcuma Domestica Extracts Compared With Ibuprofen In Patients With Knee Osteoarthritis: A Multicenter Study
In a randomized, single-blind, trial, 367 participants with knee osteoarthritis were assigned to take 1,500 mg of a turmeric extract (total curcuminoids content between 75% and 85%) or 800 mg of ibuprofen daily for 4 weeks. The primary outcomes were pain, stiffness, and function on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Both groups saw notable reductions in all measures, with no clinical or statistically significant difference between them. Adverse events were observed in 35.7% of ibuprofen users and 29.7% of turmeric extract users, with no statistically significant difference.
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of Curene® Versus Placebo In Reducing Symptoms Of Knee OA
In a randomized, double-blind, placebo-controlled trial, 50 patients with knee osteoarthritis were assigned to take 500 mg (>20% total curcuminoids) of a novel, highly bioavailable turmeric extract for 60 days. The primary outcome was a global score of osteoarthritis symptoms (WOMAC). The turmeric group saw a large, statistically significant improvement in all osteoarthritis symptoms compared with placebo, The turmeric extract group also saw a large and statistically significant reduction in pain compared with the placebo group, as measured by a visual analog scale. There was no noted difference in the rate of adverse events between groups, and the rate was low for both. The group that received the turmeric extract began to take less pain medication than the placebo group.
The Efficacy Of Curcuma Longa L. Extract As An Adjuvant Therapy In Primary Knee Osteoarthritis: A Randomized Control Trial
In a randomized, double-blind trial, 44 participants with knee osteoarthritis were assigned to take diclofenac alone or diclofenac with 500 mg of curcuminoids daily for 3 months. Both groups saw a similar reduction in pain as measured by a visual analog scale, with no statistically significant difference between them. For the Knee injury and Osteoarthritis Outcome Score, function in sport and recreation, quality of life, and symptoms categorized as 'other' were similarly improved in both groups with no statistically significant difference. The curcumin group saw a more considerable improvement in function in daily living and pain, but these weren't statistically significant.
Safety And Efficacy Of Curcumin Versus Diclofenac In Knee Osteoarthritis: A Randomized Open-label Parallel-arm Study
In a randomized, open-label comparator trial, 149 patients with knee osteoarthritis were allocated to take 500 mg of curcuminoids (BCM-95) 3 times per day or 50 mg of diclofenac twice per day for 28 days. The primary outcome was the improvement in pain on a visual analog scale (VAS), and the improvement in the curcumin group saw large and statistically significant compared with baseline and roughly the same as for diclofenac. Pain on the Knee Injury and Osteoarthritis Outcome Score was greatly improved in both groups as well, as was function and quality of life, without notable differences between them.
Curcuma Longa Extract Reduces Inflammatory And Oxidative Stress Biomarkers In Osteoarthritis Of Knee: A Four-month, Double-blind, Randomized, Placebo-controlled Trial
In a randomized, double-blind, placebo-controlled trial, 160 patients with knee osteoarthritis were allocated to take 500 mg of curcuma longa extract or placebo daily for 4 months, alongside diclofenac. The primary outcomes were pain on a visual analog scale and osteoarthritis severity on the WOMAC scale, and the intervention group saw a modestly greater improvement in pain on the visual analog scale that was statistically significant and a somewhat greater improvement in pain on WOMAC (p=0.06). There was no difference in stiffness, though there was a small, statistically significant improvement in physical function that was statistically significant between groups. There was a greater reduction in reactive oxygen species and malondialdehyde in the intervention group. Joint crepitation and effusion were also significantly reduced in the intervention group, and there were no meaningful differences in adverse events.
Glucosamine hydrochloride failed to cause a significant protective effect in osteoarthritis, while evidence on sulfate (statistically significant of a low magnitude) was said to be confounded with industry influence. No publication bias reported
The GAIT trial noted that 1500mg Glucosamine in isolation failed to significantly influence a reduction of pain in persons with osteoarthritis over 6 months; combination therapy with Chondroitin was effective only in the cohort of persons with more pain at baseline
Glucosamine Sulfate Use And Delay Of Progression Of Knee Osteoarthritis: A 3-year, Randomized, Placebo-controlled, Double-blind Study
The progression of osteoarthritis associated with 1,500mg Glucosamine sulfate for 3 years appeared to be reduced as assessed by joint space loss relative to placebo and pain.
Glucosamine Sulfate In The Treatment Of Knee Osteoarthritis Symptoms: A Randomized, Double-blind, Placebo-controlled Study Using Acetaminophen As A Side Comparator
1,500mg Glucosamine had equal efficay to 3g acetominophen for reducing joint pain in persons with osteoarthritis; this trial (the GUIDE trial) may be influenced by a producer of Glucosamine supplemnetation
Effectiveness Of Glucosamine For Symptoms Of Knee Osteoarthritis: Results From An Internet-based Randomized Double-blind Controlled Trial
(Internet based study) Mostly glucosamine sulfate, although a switch to hydrochloride for 20% of the sample was needed, failed to outperform placebo in regards to symptoms of osteoarthritis and pain.
Structural And Symptomatic Efficacy Of Glucosamine And Chondroitin In Knee Osteoarthritis: A Comprehensive Meta-analysis
A meta-analysis of 15 studies (inclusive of glucosamine and combination therapy of glucosamine with chondroitin; 7 studies used glucosamine sulfate) noted a significant effect on all measured outcomes of glucosamine treatment. Funnel plot analysis failed to find evidence of publication bias, although it appeared to trend close (and was said to be from influence from smaller studies with more effect size)
Effects Of Glucosamine, Chondroitin, Or Placebo In Patients With Osteoarthritis Of Hip Or Knee: Network Meta-analysis
A network meta-analysis on glucosamine sulfate found statistically significant pain relief, but deemed that the clinical significance of this pain relief was minimal.
2g/day of Curcumin extract has an effect equal to ibuprofen for treatment of knee osteoarthritis
Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study
In a randomized, double-blind, placebo-controlled trial, 150 participants with knee osteoarthritis were allocated to either placebo, approximately 187 mg of a turmeric rhizome extract, or 280 mg daily for 3 months. 74 participants completed the entire trial, while 141 were able to be included in the intention to treat analysis. At the end of 3 months, both curcumin groups saw a statistically significantly greater improvement in Patients Global Assessment of Disease Activity score than placebo, and there were no statistically significant differences between them. Markers of collagen breakdown were reduced significantly in the curcumin groups but not the placebo group. Pain on the visual analog scale was significantly improved compared with placebo in both curcumin groups, with no notable differences between them. Symptoms on the Knee injury and Osteoarthritis Outcome Score were improved more in the curcumin groups, with the greatest improvement in the high-dose group, but there were no statistically significant differences between groups.
Double-blind Clinical Evaluation Of Oral Glucosamine Sulphate In The Basic Treatment Of Osteoarthrosis
1,500mg Glucosamine sulfate daily over 6-8 weeks noted a reduction of pain associated with osteoarthritis when compared to placebo
A Randomized, Double-blind, Placebo-controlled Trial Of Glucosamine Sulphate As An Analgesic In Osteoarthritis Of The Knee
6 months of supplementation with 1500mg glucosamine sulfate was unable to outperform placebo.
An updated (2005) Cochrane analysis of 20 trials on glucosamine sulfate found a significant protective effect of glucosamine treatment, with the test for publication bias not reaching significance and thought to be influenced by factors not involved with publication bias (effect sizes from smaller trials)
Glucosamine hydrochloride at 1500mg daily was unable to outperform placebo during an 8 week placebo controlled study.
Glucosamine sulfate at 1,500mg for 2 months failed to significantly reduce symptoms of osteoarthritis
Ayurvedic Medicine Offers A Good Alternative To Glucosamine And Celecoxib In The Treatment Of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Controlled Equivalence Drug Trial
In persons with osteoarthritis, 2g of Glucosamine appeared to be as effective as 200mg Celecoxib over 6 months in reducing joint pain.
Long-term Effects Of Glucosamine Sulphate On Osteoarthritis Progression: A Randomised, Placebo-controlled Clinical Trial
3 years of supplementation of 1500mg Glucosamine was associated with a reduced rate of joint space loss in persons with low grade osteoarthritis.
Randomised, Double-Blind, Parallel, Placebo-Controlled Study Of Oral Glucosamine, Methylsulfonylmethane And Their Combination In Osteoarthritis
1,500mg glucosamine sulfate outperformed placebo in reducing pain in persons with knee osteoarthritis, and was additive with supplemental MSM (another group tested the combination)
Comparable Clinical Outcomes Between Glucosamine Sulfate-potassium Chloride And Glucosamine Sulfate Sodium Chloride In Patients With Mild And Moderate Knee Osteoarthritis: A Randomized, Double-blind Study
Glucosamine Sulphate as either a potassium salt or a sodium chloride salt were both effective in reducing knee osteoarthritis, with no significant differences between the two. No placebo control group.
The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomized, double-blind, placebo-controlled trial
A trial comparing the effects of milk protein on osteoarthritis using glucosamine as active control noted that, in a comparison of glucosamine to placebo, that glucosamine sulfate at 1,500mg was able to protect from osteoarthritis over 6 weeks
Glucosamine And Chondroitin For Treatment Of Osteoarthritis: A Systematic Quality Assessment And Meta-analysis
This meta-analysis was able to find a significant protective effect of glucosamine sulfate in 5 trials but also found publication bias present as assessed by funnel plot analysis
A Double Blind, Randomized, Placebo Controlled Study Of The Efficacy And Safety Of 5-Loxin For Treatment Of Osteoarthritis Of The Knee
100mg or 250mg 5-Loxin (30% AKBA) was able to confer benefits to multiple rating scales of joint pain relief in persons with osteoarthritis.
A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates The Early Efficacy Of Aflapin In Subjects With Osteoarthritis Of Knee
100mg of 20% AKBA Boswellia was able to reduce all measured parameters of osteoarthritis in persons over the course of 30 days.
Clinical Evaluation Of Boswellia Serrata (Shallaki) Resin In The Management Of Sandhivata (osteoarthritis)
6g of the basic plant Boswellia Serrata was able to significantly attenuate joint pain and symptoms in persons with osteoarthritis.
Comparative Efficacy And Tolerability Of 5-Loxin And AflapinAgainst Osteoarthritis Of The Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study
Relative to placebo, 100mg of Boswellia standardized to 30% AKBA was able to reduce joint pain and stiffness on multiple rating scales in persons with confirmed osteoarthritis over 7 days, with maximal effects over 90 days
Efficacy Of Methylsulfonylmethane Supplementation On Osteoarthritis Of The Knee: A Randomized Controlled Study
MSM supplementation at 3.375g daily for 12 weeks was associated with overall improvements in the symptoms of osteoarthritis and although a pain reducing effect was apparent it was so variable it failed to reach statistical significance. Perhaps the most marked difference was a reduction of stiffness by 26% in MSM while placebo increased 37%, but this was also so variable that it failed to reach significance. There were some differences (gender and BMI) between groups at baseline, although the MSM group tended to weigh more.
Oral supplementation of CII in young subjects with juvenile rheumatoid arthritis appeared to have benefits in reducing symptoms over the course of three months of supplementation when compared to baseline in 8/10 subjects with one remission (although spontaneous remission is possible with untreated juvenile rheumatism); there was no placebo group for comparison.
Treatment Of Osteoarthritis With Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation Of Signs, Symptoms, Physical Performance And Vascular Aspects
In persons with osteoarthritis given 100mg pycnogenol once daily for 3 months, supplementation was able to more than half (56% reduction) symptoms of osteoarhritis as assessed by the WOMAC rating scale. An improvement in functional scores and reduction in foot edema was also noted (parameter recorded under leg swelling).
Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis
In persons with primary grade 1 osteoarthritic symptoms, supplementation of pycnogenol at 50mg thrice daily was noted to, over the course of 90 days, reduce pain and functional impairment associated with osteoarthritis in the range of 35-52% (depending on what was being measured). It took 90 days for this magnitude of benefit to be see, and although all but stiffness benefitted slightly by 60 days there was no effect on day 30.
Osteoarthritis is a very common chronic condition among the elderly that incompasses bones and cartilage. Symptoms include joint pain in the hands, neck, lower back, knees or hips, as well as movement difficultness.
Related videos about Boswellia
- ^ a b Tawab MA, et al. Development of a high-performance liquid chromatographic method for the determination of 11-keto-beta-boswellic acid in human plasma. J Chromatogr B Biomed Sci Appl. (2001)
- ^ Woolley CL, et al. Chemical differentiation of Boswellia sacra and Boswellia carterii essential oils by gas chromatography and chiral gas chromatography-mass spectrometry. J Chromatogr A. (2012)
- ^ de Rapper S, et al. The additive and synergistic antimicrobial effects of select frankincense and myrrh oils–a combination from the pharaonic pharmacopoeia. Lett Appl Microbiol. (2012)
- ^ Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage. Phytother Res. (2010)
- ^ Devi PR, et al. Safety Evaluation of Alcoholic Extract of Boswellia ovalifoliolata Stem-bark in Rats. Toxicol Int. (2012)
- ^ a b c Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. (2011)
- ^ a b c d e f g h Gerbeth K, et al. Determination of major boswellic acids in plasma by high-pressure liquid chromatography/mass spectrometry. J Pharm Biomed Anal. (2011)
- ^ a b c d e f g h i j k l Moussaieff A, et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J. (2008)
- ^ Al-Harrasi A, Al-Saidi S. Phytochemical analysis of the essential oil from botanically certified oleogum resin of Boswellia sacra (Omani Luban). Molecules. (2008)
- ^ a b Wang C, et al. Determination of five boswellic acids in Boswellia serrata. Zhongguo Zhong Yao Za Zhi. (2011)
- ^ a b c Büchele B, Simmet T. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatogr B Analyt Technol Biomed Life Sci. (2003)
- ^ a b c d e f g h Moussaieff A, et al. Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals. J Psychopharmacol. (2012)
- ^ Paul M, Jauch J. Efficient preparation of incensole and incensole acetate, and quantification of these bioactive diterpenes in Boswellia papyrifera by a RP-DAD-HPLC method. Nat Prod Commun. (2012)
- ^ a b c Bhushan S, et al. A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis. (2007)
- ^ a b c Bhushan S, et al. Activation of p53/p21/PUMA alliance and disruption of PI-3/Akt in multimodal targeting of apoptotic signaling cascades in cervical cancer cells by a pentacyclic triterpenediol from Boswellia serrata. Mol Carcinog. (2009)
- ^ Schmidt TJ, Kaiser M, Brun R. Complete structural assignment of serratol, a cembrane-type diterpene from Boswellia serrata, and evaluation of its antiprotozoal activity. Planta Med. (2011)
- ^ Two triterpenoids from Boswellia serrata gum resin.
- ^ TETRACYCLIC TRITERPENE ACIDS FROM RESIN OF BOSWELLIA-SERRATA ROXB.
- ^ Song Z, et al. Determination of alpha-pinene and octyl acetate contents in Boswellia serrata. Zhongguo Zhong Yao Za Zhi. (2012)
- ^ a b c d e f Khajuria A, et al. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata. Phytother Res. (2008)
- ^ The structure of incensole.
- ^ a b c d Roy S, et al. Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to antiinflammatory Boswellia. Antioxid Redox Signal. (2006)
- ^ Sengupta K, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. (2011)
- ^ a b c d e f g Takada Y, et al. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol. (2006)
- ^ Kumar A, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl). (2004)
- ^ Ozes ON, et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. (1999)
- ^ Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. (2002)
- ^ Nakayama T, Sawada T. Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav. (2002)
- ^ Trojanowski JQ, et al. Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments. Expert Opin Pharmacother. (2005)
- ^ Nelson R. Microtubule-stabilising drugs may be therapeutic in AD. Lancet Neurol. (2005)
- ^ Avila J, et al. Role of tau protein in both physiological and pathological conditions. Physiol Rev. (2004)
- ^ a b Karima O, et al. An in vitro study of the role of β-boswellic acid in the microtubule assembly dynamics. FEBS Lett. (2012)
- ^ a b Karima O, et al. The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study). Neurol Sci. (2010)
- ^ Krüger P, et al. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sci. (2009)
- ^ Krishna G, et al. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm. (2001)
- ^ a b c d e f g h Gerbeth K, et al. In vitro metabolism, permeation, and brain availability of six major boswellic acids from Boswellia serrata gum resins. Fitoterapia. (2012)
- ^ a b c d e f g h i Hüsch J, et al. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia. (2012)
- ^ Hüsch J, et al. Effect of Phospholipid-Based Formulations of Boswellia serrata Extract on the Solubility, Permeability, and Absorption of the Individual Boswellic Acid Constituents Present. J Nat Prod. (2012)
- ^ Sharma A, Gupta NK, Dixit VK. Complexation with phosphatidyl choline as a strategy for absorption enhancement of boswellic acid. Drug Deliv. (2010)
- ^ a b c Reising K, et al. Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem. (2005)
- ^ a b c Tausch L, et al. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol. (2009)
- ^ Sterk V, Büchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. (2004)
- ^ a b c d Skarke C, et al. Increased bioavailability of 11-keto-β-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: modeling and simulation considerations for evaluating drug exposures. J Clin Pharmacol. (2012)
- ^ a b Siemoneit U, et al. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol. (2009)
- ^ Krüger P, et al. Metabolism of boswellic acids in vitro and in vivo. Drug Metab Dispos. (2008)
- ^ Weber CC, et al. Modulation of Pgp function by boswellic acids. Planta Med. (2006)
- ^ Chung MK, et al. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J Biol Chem. (2004)
- ^ Xu H, et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature. (2002)
- ^ Smith GD, et al. TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature. (2002)
- ^ a b Bakthira H, et al. Anticholinesterase activity of endemic plant extracts from Soqotra. Afr J Tradit Complement Altern Med. (2011)
- ^ a b c Moussaieff A, et al. Protective effects of incensole acetate on cerebral ischemic injury. Brain Res. (2012)
- ^ a b c Streffer JR, et al. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology. (2001)
- ^ a b c Winking M, et al. Boswellic acids inhibit glioma growth: a new treatment option. J Neurooncol. (2000)
- ^ Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. (2012)
- ^ Leroux E, Ducros A. Cluster headache. Orphanet J Rare Dis. (2008)
- ^ a b Mahmoudi A, et al. Evaluation of systemic administration of Boswellia papyrifera extracts on spatial memory retention in male rats. J Nat Med. (2011)
- ^ Roy S, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol. (2005)
- ^ a b c Cuaz-Pérolin C, et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol. (2008)
- ^ a b c d e f g h Sengupta K, et al. Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. (2010)
- ^ The IκB Kinase (IKK) Inhibitor, NEMO-binding Domain Peptide, Blocks Osteoclastogenesis and Bone Erosion in Inflammatory Arthritis.
- ^ Abu-Amer Y, Tondravi MM. NF-kappaB and bone: the breaking point. Nat Med. (1997)
- ^ Kulkarni RR, et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. (1991)
- ^ Chopra A, et al. Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol. (2000)
- ^ a b Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. (2011)
- ^ a b Sengupta K, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. (2008)
- ^ a b Gupta PK, et al. Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis). Ayu. (2011)
- ^ Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res. (2007)
- ^ Cassileth B. Complementary therapies, herbs, and other OTC agents: Boswellia (Boswellia serrata). Oncology (Williston Park). (2009)
- ^ Martínez-Clemente M, Clària J, Titos E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Curr Opin Clin Nutr Metab Care. (2011)
- ^ Gupta I, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. (1997)
- ^ a b Sailer ER, et al. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. (1996)
- ^ Safayhi H, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. (1992)
- ^ Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. (1995)
- ^ Ammon HP, et al. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. (1993)
- ^ Siemoneit U, et al. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol. (2008)
- ^ a b c d Ammon HP. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine. (2010)
- ^ Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem. (2006)
- ^ Inhibition of IκB Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo.
- ^ a b Acetyl-Boswellic Acids Inhibit Lipopolysaccharide-Mediated TNF-α Induction in Monocytes by Direct Interaction with IκB Kinases.
- ^ a b c d e Henkel A, et al. Boswellic acids from frankincense inhibit lipopolysaccharide functionality through direct molecular interference. Biochem Pharmacol. (2012)
- ^ Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. (1976)
- ^ Moussaieff A, et al. Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol. (2007)
- ^ Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. (2006)
- ^ a b Siemoneit U, et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br J Pharmacol. (2011)
- ^ Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. (2007)
- ^ Verhoff M, et al. A novel C(28)-hydroxylated lupeolic acid suppresses the biosynthesis of eicosanoids through inhibition of cytosolic phospholipase A(2). Biochem Pharmacol. (2012)
- ^ a b c Safayhi H, et al. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther. (1997)
- ^ a b Kapil A, Moza N. Anticomplementary activity of boswellic acids–an inhibitor of C3-convertase of the classical complement pathway. Int J Immunopharmacol. (1992)
- ^ a b c d e Immunomodulatory Activity of Boswellic Acids (Pentacyclic Triterpene Acids) from Boswellia serrata.
- ^ Khajuria A, et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine. (2007)
- ^ a b Immunomodulatory Triterpenoids from the Oleogum Resin of Boswellia carterii Birdwood.
- ^ a b Shehata AM, et al. Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE). Phytomedicine. (2011)
- ^ a b c d e Yuan HQ, et al. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol. (2008)
- ^ Rollinger JM, et al. 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches. Bioorg Med Chem. (2010)
- ^ a b Borrelli F, et al. Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation. Br J Pharmacol. (2006)
- ^ a b Latella G, et al. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest. (2008)
- ^ Ke F, Yadav PK, Ju LZ. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol. (2012)
- ^ a b Hartmann RM, et al. Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci. (2012)
- ^ a b Anthoni C, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. (2006)
- ^ Rhodes JM, et al. Serum inhibitors of leukocyte chemotaxis in Crohn’s disease and ulcerative colitis. Gastroenterology. (1982)
- ^ Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. (2008)
- ^ Madisch A, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. (2007)
- ^ Slonim AE, Grovit M, Bulone L. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn’s disease. J Am Coll Nutr. (2009)
- ^ a b c Holtmeier W, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. (2011)
- ^ a b Raja AF, et al. Acetyl-11-keto-β-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res Notes. (2011)
- ^ Schillaci D, et al. In vitro anti-biofilm activity of Boswellia spp. oleogum resin essential oils. Lett Appl Microbiol. (2008)
- ^ a b Mahmoud MF, Diaai AA, Ahmed F. Evaluation of the efficacy of ginger, Arabic gum, and Boswellia in acute and chronic renal failure. Ren Fail. (2012)
- ^ Gupta I, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. (1998)
- ^ Clark CE, et al. Herbal interventions for chronic asthma in adults and children: a systematic review and meta-analysis. Prim Care Respir J. (2010)
- ^ a b Houssen ME, et al. Natural anti-inflammatory products and leukotriene inhibitors as complementary therapy for bronchial asthma. Clin Biochem. (2010)
- ^ a b Lakka A, et al. Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. Invest New Drugs. (2011)
- ^ Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. (2002)
- ^ Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs. (2005)
- ^ a b c d e f Pang X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. (2009)
- ^ a b c Hoernlein RF, et al. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther. (1999)
- ^ Castelli S, et al. Interaction between natural compounds and human topoisomerase I. Biol Chem. (2012)
- ^ On the expression and regulation of 5-lipoxygenase in human lymphocytes.
- ^ a b c d Glaser T, et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. (1999)
- ^ Glioblastoma multiforme: Morphology and biology.
- ^ a b Flavin DF. A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol. (2007)
- ^ Shen Y, et al. Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells. Cancer Biol Ther. (2012)
- ^ a b Takahashi M, et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. (2012)
- ^ Liu JJ, Duan RD. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. Anticancer Res. (2009)
- ^ Liu HP, et al. Chemoprevention of intestinal adenomatous polyposis by acetyl-11-keto-beta-boswellic acid in APC(Min/+) mice. Int J Cancer. (2012)
- ^ Suh J, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate. (2002)
- ^ Büchele B, et al. Characterization of 3alpha-acetyl-11-keto-alpha-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med. (2006)
- ^ Lu M, et al. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. (2008)
- ^ Kim HR, et al. Bosellia serrata-induced apoptosis is related with ER stress and calcium release. Genes Nutr. (2008)
- ^ Khan S, et al. A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur J Pharmacol. (2011)
- ^ Kaur R, et al. A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid. Eur J Med Chem. (2011)
- ^ a b Aggarwal BB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. (2006)
- ^ Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression.
- ^ a b c d Kunnumakkara AB, et al. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res. (2009)
- ^ Gene Silencing of the Tyrosine Phosphatase SHP1 Gene by Aberrant Methylation in Leukemias/Lymphomas.
- ^ a b c d e f g Park B, et al. Acetyl-11-keto-β-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Int J Cancer. (2011)
- ^ Suhail MM, et al. Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells. BMC Complement Altern Med. (2011)
- ^ Mothana RA, et al. Studies of the in vitro anticancer, antimicrobial and antioxidant potentials of selected Yemeni medicinal plants from the island Soqotra. BMC Complement Altern Med. (2009)
- ^ Koshiba T, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. (2000)
- ^ a b c d e Park B, et al. Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. PLoS One. (2011)
- ^ Ni X, et al. Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model. BMC Complement Altern Med. (2012)
- ^ Safayhi H, Sailer ER. Anti-inflammatory actions of pentacyclic triterpenes. Planta Med. (1997)
- ^ a b c Pedretti A, et al. Effects of topical boswellic acid on photo and age-damaged skin: clinical, biophysical, and echographic evaluations in a double-blind, randomized, split-face study. Planta Med. (2010)
- ^ a b Calzavara-Pinton P, et al. Topical Boswellic acids for treatment of photoaged skin. Dermatol Ther. (2010)
- ^ a b Krishnaraju AV, et al. Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. (2010)
- ^ Tripathi YB. BHUx: a patented polyherbal formulation to prevent hyperlipidemia and atherosclerosis. Recent Pat Inflamm Allergy Drug Discov. (2009)
- ^ a b c d Su S, et al. Evaluation of the anti-inflammatory and analgesic properties of individual and combined extracts from Commiphora myrrha, and Boswellia carterii. J Ethnopharmacol. (2012)
- ^ a b Sferra R, et al. Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TGF-beta1 downregulation. Eur Rev Med Pharmacol Sci. (2012)
- ^ a b Lalithakumari K, et al. Safety and Toxicological Evaluation of a Novel, Standardized 3-O-Acetyl-11-keto-beta-Boswellic Acid (AKBA)-Enriched Boswellia serrata Extract (5-Loxin(R)). Toxicol Mech Methods. (2006)
- ^ Lupi S, et al. Mutagenicity evaluation with Ames test of hydro-alcoholic solution of terpenes. J Prev Med Hyg. (2009)
- ^ Sharma R, et al. In vivo genotoxicity evaluation of a plant based antiarthritic and anticancer therapeutic agent Boswelic acids in rodents. Phytomedicine. (2009)
- ^ Acebo E, et al. Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. Contact Dermatitis. (2004)